During Wednesday’s Current trade, Shares of Terex Corporation(NYSE:TEX), gain 3.48% to $21.69.
Terex Corporation (TEX) declared income from ongoing operations of $85.2 million, or $0.78 per share for the second quarter of 2015, as contrast to income from ongoing operations of $87.8 million, or $0.76 per share for the second quarter of 2014. Net sales were $1,828.5 million in the second quarter of 2015, a decrease of $226.6 million, or 11.0%, when contrast with $2,055.1 million in the second quarter of 2014. Not taking into account the impact of currency, net sales declined about 2.0%. Income from operations was $148.3 million in the second quarter of 2015, a decrease of $12.6 million when contrast to income from operations of $160.9 million in the second quarter of 2014.
Terex Corporation operates as a lifting and material handling solutions company. Its Aerial Work Platforms segment designs, manufactures, services, and markets aerial work platform equipment, telehandlers, and light towers, in addition to related components and replacement parts under Terex and Genie names. The company’s Construction segment offers compact construction equipment, counting loader backhoes, mini and midi excavators, wheeled excavators, site dumpers, compaction rollers, skid steer loaders, and wheel loaders; and specialty equipment, such as material handlers, concrete mixer trucks, and concrete pavers. Its Cranes segment designs, manufactures, services, refurbishes, and markets mobile telescopic, tower, lattice boom crawler, lattice boom truck, utility equipment, and truck-mounted cranes, in addition to related components and replacement parts under Terex name.
Shares of TerraForm Power Inc (NASDAQ:TERP), declined -1.29% to $19.90, during its current trading session.
SunEdison, Inc. (SUNE), the world’s largest renewable energy development company, and West Street Infrastructure Partners III (“WSIP”) and associates, recently declared the formation of a new $1 billion warehouse investment vehicle, the WSIP Warehouse, to fund construction costs and to acquire operating assets. TerraForm Power, Inc. (TERP), a global owner and operator of clean energy power plants, will have an exclusive call right over the warehoused assets.
The WSIP Warehouse is a $1 billion investment vehicle with $300 million equity committed, subject to certain conditions, by WSIP, the infrastructure fund managed by Goldman Sachs. The debt structuring will be led by Morgan Stanley, Bank of America and Deutsche Bank and will provide commitments for $700 million of debt in the form of a $500 million, five-year term loan and a $200 million, four-year revolving credit facility. SunEdison has the option to expand the facility by up to $1 billion to a total of $2 billion, subject to certain conditions.
TerraForm Power, Inc. owns and operates solar and wind generation assets serving utility, commercial, and residential customers. As of February 20, 2015, its portfolio compriseed of solar and wind projects located in the United States, Canada, the United Kingdom, and Chile with an aggregate nameplate capacity of 1,507.3 megawatt. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. The company was founded in 2014 and is based in Bethesda, Maryland. TerraForm Power, Inc. is a partner of SunEdison, Inc.
Tesoro Corporation (NYSE:TSO), during its Wednesday’s current trading session decreased -0.51% to $87.76.
Tesoro Corporation ( TSO ) stated second quarter 2015 net earnings of $582 million, or $4.59 per diluted share contrast to net earnings of $224 million, or $1.70 per diluted share for the second quarter of 2014. Net earnings from ongoing operations for the second quarter were $586 million or $4.62 per diluted share. Adjusted EBITDA for the second quarter 2015 was $1.2 billion contrast to $548 million last year.
For the second quarter 2015, the Company recorded segment operating income of $1.1 billion contrast to segment operating income of $494 million in the second quarter of 2014. The enhance was largely driven by strong demand, continued growth in the logistics segment and business improvements.
The refining segment`s operating income was $753 million for the quarter, contrast to $358 million in the second quarter of 2014. Our refineries benefited from a substantially improved margin environment and lower operating expenses partially offset by turnarounds and maintenance activities.
Tesoro Corporation, through its auxiliaries, engages in petroleum refining and marketing activities in the United States. It operates in three segments: Refining, Tesoro Logistics LP (TLLP), and Retail. The Refining segment refines crude oil and other feed stocks into transportation fuels, such as gasoline, gasoline blend stocks, jet fuel, and diesel fuel, in addition to other products, counting heavy fuel oils, liquefied petroleum gas, petroleum coke, calcined coke, and asphalt.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), decreased -0.93%, to $2.65.
Arena Pharmaceuticals, Inc. (ARNA) stated financial results for the second quarter ended June 30, 2015, and offered a corporate update.
Second Quarter and Recent Developments
Arena Research & Development
- Declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
- Arena and Roivant Sciences Ltd. reached a Development, Marketing and Supply Agreement for nelotanserin, Arena’s internally discovered inverse agonist of the serotonin 2A receptor.
- Declared results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development as a potential treatment for pain.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
